Tag Archives: Merck

Merck looks for leg up on Bristol with Keytruda’s latest colorectal cancer win

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won. The immuno-oncology star trumped various chemo regimens at keeping cancer from progressing in previously untreated patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that had either spread to other parts of the body or couldn’t be surgically removed,… Read More: Merck looks for leg up on Bristol with Keytruda’s latest… »

Merck abandons $7M in grants for long-term IT hiring plan in Austin

When Merck moseyed into the Lone Star State as part of a global IT restructuring, it pitched a robust hiring plan in exchange for nearly $ 7 million in tax breaks and grants. Now, after Merck pulled back the reins on its Austin plans, those incentives have dried up. Merck is walking away from incentive… Read More: Merck abandons $7M in grants for long-term IT hiring plan… »

Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure

Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More: Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian… »

Palantir to offer cancer analytics under JV deal with Germany's Merck

((This NOV 19 story corrects to show Merck is Palantir’s exclusive partner within the JV, not for all of Palantir’s healthcare activities, paragraph 11)) FILE PHOTO: Merck CEO Stefan Oschmann delivers a speech during the celebrations of the 350th anniversary of German pharmaceuticals company Merck at the Merck headquarters in Darmstadt, Germany, May 3 ,2018.… Read More: Palantir to offer cancer analytics under JV deal with Germany's… »